Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter

Schwille‐Kiuntke, Juliane; Enck, Paul; Zendler, C.; Krieg, Marc Antoine; Polster, Annikka; Klosterhalfen, Sibylle; Autenrieth, Ingo B.; Zipfel, Stephan; Frick, Julia-Stefanie

doi:10.1111/j.1365-2982.2011.01779.x

Cited by 94 publications

(72 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Symptoms of dyspepsia at an 8-year follow-up were also significantly more prevalent in those exposed to gastroenteritis than in those who were unaffected [70]. A similar study from Europe identified that 10 % of patients with an intestinal bacterial infection report postinfectious symptoms up to 10 years after the infectious event, and revealed four significant factors affecting the occurrence of postinfectious IBS symptoms: namely, gender (female), severe symptoms during the infection, infected by Salmonella as opposed to Escherichia coli, and higher anxiety, depression and somatization baseline scores [71]. Although infection is now an established cause of FGIDs, and may account for some cases with both IBS and FD, Koch's postulates have not been completely fulfilled, and there is no work on modification of this risk in preventing a later FGID.…”

Section: Postinfectious Fgidsmentioning

confidence: 90%

Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology

2015

View full text Add to dashboard Cite

Functional gastrointestinal disorders (FGIDs) are common and distressing. They are so named because a defined pathophysiology in terms of structural or biochemical pathways is lacking. Traditionally FGIDs have been conceptualized as brain-gut disorders, with subgroups of patients demonstrating visceral hypersensitivity and motility abnormalities as well as psychological distress. However, it is becoming apparent that there are certain structural or biochemical gut alterations among subsets with the common FGIDs, most notably functional dyspepsia (FD) and irritable bowel syndrome (IBS). For example, a sodium channel mutation has been identified in IBS that may account for 2 % of cases, and subtle intestinal inflammation has been observed in both IBS and FD. Other research has implicated early life events and stress, autoimmune disorders and atopy and infections, the gut microbiome and disordered mucosal immune activation in patients with IBS or FD. Understanding the origin of symptoms in FGIDs will allow therapy to be targeted at the pathophysiological changes, not at merely alleviating symptoms, and holds hope for eventual cure in some cases.For example, there are promising developments in manipulating the microbiome through diet, prebiotics and antibiotics in IBS, and testing and treating patients for Helicobacter pylori infection remains a mainstay of therapy in patients with dyspepsia and this infection. Locally acting drugs such as linaclotide have been an advance in treating the symptoms of constipation-predominant IBS, but do not alter the natural history of the disease. A role for a holistic approach to patients with FGIDs is warranted, as brain-togut and gut-to-brain pathways appear to be activated.

show abstract

Section: Postinfectious Fgidsmentioning

confidence: 90%

Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology

2015

View full text Add to dashboard Cite

show abstract

“…Furthermore, long-term follow-up studies have revealed that C. jejuni-associated postinfectious IBS symptoms can persist for up to 10 years after the infectious event (165,166). Current evidence suggests that both bacterial and host factors play a crucial role in the predisposition to C. jejuni-associated postinfectious IBS.…”

Section: Functional Gastrointestinal Disordersmentioning

confidence: 99%

Global Epidemiology of Campylobacter Infection

et al. 2015

View full text Add to dashboard Cite

SUMMARY Campylobacter jejuni infection is one of the most widespread infectious diseases of the last century. The incidence and prevalence of campylobacteriosis have increased in both developed and developing countries over the last 10 years. The dramatic increase in North America, Europe, and Australia is alarming, and data from parts of Africa, Asia, and the Middle East indicate that campylobacteriosis is endemic in these areas, especially in children. In addition to C. jejuni , there is increasing recognition of the clinical importance of emerging Campylobacter species, including Campylobacter concisus and Campylobacter ureolyticus . Poultry is a major reservoir and source of transmission of campylobacteriosis to humans. Other risk factors include consumption of animal products and water, contact with animals, and international travel. Strategic implementation of multifaceted biocontrol measures to reduce the transmission of this group of pathogens is paramount for public health. Overall, campylobacteriosis is still one of the most important infectious diseases that is likely to challenge global health in the years to come. This review provides a comprehensive overview of the global epidemiology, transmission, and clinical relevance of Campylobacter infection.

show abstract

“…These species may increase the risk of PI-IBS 6-fold. 62,63 An interesting study from 2012 including 37 IBS patients reported significantly different IBS subgroups based on microbiota datasets using clustering analysis. 64 This was the first study to demonstrate an IBS subgroup with no detectable changes in fecal microbiota.…”

Section: Colonization In Early Lifementioning

confidence: 99%

Irritable bowel syndrome, the microbiota and the gut-brain axis

Raskov¹,

et al. 2016

View full text Add to dashboard Cite

Irritable bowel syndrome is a common functional gastrointestinal disorder and it is now evident that irritable bowel syndrome is a multi-factorial complex of changes in microbiota and immunology. The bidirectional neurohumoral integrated communication between the microbiota and the autonomous nervous system is called the gut-brain-axis, which integrates brain and GI functions, such as gut motility, appetite and weight. The gut-brain-axis has a central function in the perpetuation of irritable bowel syndrome and the microbiota plays a critical role. The purpose of this article is to review recent research concerning the epidemiology of irritable bowel syndrome, influence of microbiota, probiota, gut-brainaxis, and possible treatment modalities on irritable bowel syndrome. The integrated actions and communication between the microbiota and the autonomous nervous system are central players in the perpetuation of IBS symptoms. This signaling pathway is called the GutBrain Axis (GBA). The GBA is a bidirectional neurohumoral communication system that integrates brain and GI functions, such as gut motility, appetite and weightand here the microbiota plays a critical role. 2Changes in gastrointestinal or central nervous system physiology may result in an altered habitat, which again may cause changes in the composition of the microbiota.Disruption of the physiologic symbiotic relationship (eubiosis) between the human host and the microbiota is called dysbiosis and is regarded a basic factor for initiating and maintaining IBS in the majority of patients. Current evidence has suggested that the dysbiosis observed in IBS and the resulting immunological response may drive and perpetuate gastrointestinal symptoms of IBS suggesting that IBS is in fact a disorder of the microbiota and the GBA. It is unclear whether the initiating factor is brain abnormalities that drive the gut changes or if changes in the gut alter brain function through vagal and sympathetic pathways.3,4 The purpose of this article is to review recent research concerning the influence of microbiota and gut-brain-axis on IBS. IBSIt is estimated that approximately 10% of the World population and 15% of the population in the Western World suffer from IBS characterized by a mixture of recurrent abdominal pain, bloating, changing stool consistency such as diarrhea (IBS-D), constipation (IBS-C), or interchanging diarrhea and constipation (mixed-type or IBS-M), mucus secretion, and nausea. 5,6 Community-based data indicate that IBS-M is the most prevalent type followed by IBS-D and IBS-C and that switching among subtypes occurs. Bloating is the most prevalent symptom reported by 96% of patients with IBS of whatever subgroup. 7 In addition to abdominal symptoms, poor sleep, headache, CONTACT Hans Raskov raskov@mail.dk Lundevangsvej 23, DK-2900 Hellerup, Denmark. Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/kgmi.

show abstract

Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter

Abstract: Nearly 10% of patients with an intestinal bacterial infection report postinfectious symptoms up to 10 years after the infectious event. They represent a clinically important population with high psychiatric comorbidity and somatic symptom burden.

Cited by 94 publications

References 41 publications

Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology

Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology

Global Epidemiology of Campylobacter Infection

Irritable bowel syndrome, the microbiota and the gut-brain axis

Contact Info

Product

Resources

About